jobs.jnj.com/en/jobs/
Skip to content

Internet Explorer is no longer supported by this website.

For optimal browsing we recommend using Chrome, Firefox or Safari.
Heart icon (animated) heart icon (static)
Share
Did you like reading this story? Click the heart to show your love.
Empty Heart Icon
108
Latest News

Johnson & Johnson Executive Jennifer Taubert Named to Fortune’s 2022 Most Powerful Women List

Share
Did you like reading this story? Click the heart to show your love.
Empty Heart Icon
108
The company leader has been named to the prestigious list—which honors 50 women at the top of their industries—for the seventh year in a row.
Today's Top Reads Close

As a testament to her leadership and influence, Jennifer Taubert, Executive Vice President and Worldwide Chairman, Pharmaceuticals at Johnson & Johnson, has been named to Fortune’s 2022 list of the Most Powerful Women for the seventh consecutive year.

The annual ranking is based on five criteria: the size and importance of a leader’s business in the global economy, the health and direction of the business, the arc of her career, her social and cultural influence and how she uses her position to help shape her company and the world beyond.

Taubert checks all those boxes.

Dedication to Putting Patients First

As head of the Janssen Pharmaceutical Companies of Johnson & Johnson, Taubert is charged with guiding Janssen’s global efforts to develop and deliver innovative medicines to transform the lives of millions around the world.

In the past year alone, that strategy has led to a number of “firsts” for novel therapies, including the launch of Janssen’s first cell therapy, for multiple myeloma; a treatment for non-small cell lung cancer for patients with a specific genetic mutation; and a twice-yearly injectable for schizophrenia in adults.

In 2021, Janssen invested $11.9 billion in research and development, a 24% increase over 2020, demonstrating Taubert's ongoing commitment to tackling some of the world's most devastating diseases today and in the future. Indeed, as the latest U.S. Transparency Report shows, Janssen is among the top investors in R&D across all industries worldwide.

“Jennifer has dedicated her career to making a global impact in healthcare. At Johnson & Johnson that means putting patients and all those we serve at the center of everything we do,” says Joaquin Duato, Chief Executive Officer, Johnson & Johnson. “She is an inspirational leader and truly deserving of this recognition once again.”

Commitment to the Company's Values

Taubert has leveraged her influence to advance a culture of diversity, equity and inclusion at Johnson & Johnson. As Executive Committee sponsor of the company’s Alliance for Diverse Abilities Employee Resource Group, she’s championed a number of initiatives that support employees living with diverse physical, neurological and mental health abilities. And that’s not all.

Recognizing the COVID-19 pandemic’s continuing toll on frontline workers, she also drives the company’s support for nurses and other critical healthcare providers; most notably, Johnson & Johnson’s support for the Dr. Lorna Breen Health Care Provider Protection Act, the first national legislation to improve the mental health and well-being of U.S. health workers.

Johnson & Johnson applauds Taubert on this repeat honor, which reflects her unwavering commitment to helping change the trajectory of human health.

Did you like reading this story? Click the heart to show your love.
Empty Heart Icon
108
Read about the many ways the company is invested in supporting women as they work to help change the trajectory of health for humanity.

More from Johnson & Johnson

This site uses cookies as described in our Cookie Policy. Please click the "Accept" button or continue to use our site if you agree to our use of cookies.
Close cookie banner icon
Back to top
You are now leaving jnj.com. The site you’re being redirected to is a branded pharmaceutical website. Please click below to continue to that site.
Continue